Compare Moderna, Inc. (MRNA) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Msci Inc — how do they compare? Moderna, Inc. trades at $224.87 (market cap $78.65B), while Msci Inc trades at $565.48 (market cap $40.38B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Msci Inc pays a 1.48% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Msci Inc for 82 Days on average.
| MRNA | MSCI | |
|---|---|---|
Market Cap | $78.65B | $40.38B |
Volume | 37,373,437 | 414,140 |
Sector | Health | Financials |
52-Week High | $203.46 | $643.83 |
52-Week Low | $22.36 | $511.84 |
Typical Hold Time | 59 Days | 82 Days |
Enterprise Value | $74.80B | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
MSCI trades at $565.12, up 1.75% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $3.13B, net income of $1.20B, and high margins. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 slightly missed. The company maintains strong cash flow and completed the acquisition of First Street in August 2026, enhancing its climate risk analytics offerings.
Outlook remains positive with a consensus price target of $701.71, implying significant upside. Key opportunities include recurring revenue growth and expansion in private markets. Risks include high valuation multiples, debt levels, and market sensitivity to financial services demand. Investors should weigh strong profitability against premium pricing and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
